Last reviewed · How we verify
NCT07475234: RAG-MPDAC
A Phase Ib/II Single-Arm, Single-Center, Prospective Clinical Study Of Rimegepant Combined With AG Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 trial testing Rimegepant plus Nab-Paclitaxel and Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma in 30 participants. Not yet recruiting.
1 December 2028
Quick facts
| Lead sponsor | Xiuchao Wang |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 March 2026 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
Drugs / interventions tested
- Rimegepant plus Nab-Paclitaxel and Gemcitabine — full drug profile →
Conditions studied
- Metastatic Pancreatic Ductal Adenocarcinoma — all drugs for Metastatic Pancreatic Ductal Adenocarcinoma →
Sponsor
Xiuchao Wang — full company profile →
Who can join
18 and older, any sex, with Metastatic Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Progression-Free Survival
Time frame: From randomization to disease progression or death, with follow-up for up to 2 years after treatment initiation.
Time from randomization to disease progression or death from any cause, assessed per RECIST v1.1 and evaluated every 6 weeks during treatment and follow-up.
Sponsor's own description
This study aims to evaluate the efficacy and safety of Rimegepant combined with AG chemotherapy as first-line treatment for metastatic pancreatic cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07475234
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT06904378 — ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
- NCT07214298 — Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
- NCT07089940 — OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma · EARLY_PHASE1 · recruiting
- NCT06989437 — A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif · Phase 2, PHASE3 · recruiting
- NCT07096362 — Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07475234 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiuchao Wang
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07475234.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing